$PRAH News

Last published 1y ago

1y agoAKYA CMBM CSCO DOMO+9Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix BoardBusiness WireBelieves Incumbent Board's Approval and Ongoing Pursuit of Reckless and Dilutive Proposed Merger with Akoya Biosciences Demonstrates Urgent Need for Refreshment
4y agoPRAHDose-Response in PD and Safety of Cofact Under VKA Anticoagulation - NCT05205863ClinicalTrials.govPeak thrombin generation at 30 minutes after end of the Cofact infusion, Changes in ETP, Concentration in clotting factors, (and 3 more...)
5y agoPRAHA Phase 1b, Randomized, 2-Part Evaluation of Oral PF614 Relative to OxyContin - NCT05043766ClinicalTrials.govIncidence of Treatment-Emergent Adverse Events [Safety and Tolerability], Pharmacokinetics AUC [Area Under the Curve], Pharmacokinetics Cmax [Maximum Plasma Concentration], (and 23 more...)
5y agoRDUS PRAHRWE Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women - NCT04974723ClinicalTrials.govTime to first incidence of nonvertebral fracture, Time to the first incidence of a composite of nonfatal MI, nonfatal stroke, or in-hospital cardiovascular death, Time to the first incidence of a composite nonfatal MI, nonfatal stroke, heart failure or in-hospital cardiovascular death
5y agoDTE ICLR PRAH SPGI+1DT Midstream Set to Join S&P MidCap 400PR NewswireNEW YORK, June 28, 2021 /PRNewswire/ -- DT Midstream Inc. (NYSE:DTM) will replace PRA Health Sciences Inc. (NASD: PRAH) in the S&P MidCap 400 effective prior to the open on Friday, July 2. ICON plc (NASD: ICLR) is acquiring PRA Health Sciences in a deal
5y agoMDRX PRAHVeradigm and PRA Health Sciences Partner to Create the Industry's Leading EHR-Based Clinical Research NetworkBusiness WireThrough this strategic partnership, the network aims to reach more than 25,000 physicians and 40 million patients, accelerating trial recruitment and enrollment efforts and expanding patients' access to clinical research Veradigm®, a leading provide
5y agoPRAHVeranex Announces Investment From Summit Partners to Form Comprehensive Concept-to-Commercialization Medtech Services CompanyBusiness WireVeranex today announced the formation of the first concept-to-commercialization global service provider dedicated to the medtech industry. Formed in partnership with global growth investor Summit Partners, the Veranex platform is designed to provide the
5y agoAVXL PRAH TMDXAnavex Life Sciences Announces Appointment of Ms Jiong Ma, PhD to Board of DirectorsGlobeNewswireStrengthening Board of Directors with Expertise in Innovative Product Launches NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing dif
5y agoPRAHPRA Health Sciences pioneers connecting clinical trial patients with their real-world data with SynomaGlobeNewswireRALEIGH, N.C., May 13, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) announced today an innovative tokenization solution using Synoma®, PRA's proprietary technology that allows for the generation of enhanced evidence for drug develo
5y agoPRAHPRA Health Sciences, Inc. Reports First Quarter 2021 ResultsGlobeNewswireNet new business of $797.2 million; representing growth of 31.8%; Net book-to-bill of 1.24 excluding reimbursement revenue Net new business of $1,154.4 million; representing growth of 20.8%; Net book-to-bill of 1.33 including reimbursement revenue $93
5y agoPRAHRandomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension - NCT04857840ClinicalTrials.govThe primary efficacy endpoint is the change from baseline in systolic AOBP at Week 12.
5y agoPRAHPRA Health Sciences expands its response to COVID-19 with pharmacovigilance solutions for authorized vaccines and therapeuticsGlobeNewswireRALEIGH, N.C., April 21, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ:PRAH) announced today the expansion of its pharmacovigilance solution to offer full post-marketing services for authorized COVID-19 vaccines and therapeutics, including post-
5y agoGILD CG PRAH TMO+1Thermo to Buy PPD for $17.4 Billion as Health Deals SoarBloomberg
5y agoPRAHPRA Health Sciences selected by Maryland State Medical Society to supply remote patient monitoring and telehealth servicesGlobeNewswireRALEIGH, N.C. and BALTIMORE, April 13, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) and the Maryland State Medical Society (MedChi) announced today that Care Innovations, a PRA Health...
5y agoPRAHPRA’s remote patient monitoring platform selected by Merck KGaA, Darmstadt, Germany to work in combination with its human growth hormone treatment systemGlobeNewswireRALEIGH, N.C. , April 07, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today that Merck KGaA, Darmstadt, Germany, known in the United States as EMD Serono, selected PRA’s...
5y agoPRAHPRA’s Center for Rare Diseases Launches Toolkit to Identify and Mitigate Risks to Rare Disease Clinical ProgramsGlobeNewswireRALEIGH, N.C., March 22, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today the launch of its Patient-Centric Trial Development Toolkit, available now to clinical...
5y agoRTP PRAH SFTW PANDMoore Kuehn Encourages SFTW, PRAH, RTP, and PAND Investors to Contact Law FirmGlobeNewswireNEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
5y agoBNTX PFE PRAHCovid Researchers Icon, PRA Health Join in $12 Billion DealBloombergIcon Plc agreed to buy PRA Health Sciences Inc. in a $12 billion cash and stock deal that combines two research providers supporting Covid vaccine and treatment trials.
5y agoPRAHPRA Health Sciences, Inc. Reports Fourth Quarter and Full Year 2020 ResultsGlobeNewswireNet new business of $872.4 million in the fourth quarter excluding reimbursement revenue; representing growth of 32.4%; Net book-to-bill of 1.42Net new business of $1,437.8 million in the fourth...
5y agoICLR PRAHICON to Acquire PRA Health Sciences, Creating a World Leader in Healthcare Intelligence and Clinical ResearchBusiness WireDUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR), a global provider of outsourced drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, and government and public health organisations, today announced it has entered into a definitive agreement to acquire PRA Health Sciences, Inc. (NASDAQ: PRAH) in a cash and stock transaction ...
5y agoPRAHPRA Health Sciences to Report Fourth Quarter and Full Year 2020 EarningsGlobeNewswireRALEIGH, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its fourth quarter and full year 2020 results after the market closes on Thursday, February 25,...
5y agoPRAHStudy to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT. - NCT04731298ClinicalTrials.govSerum concentrations of free emapalumab, Serum concentration of free and total Interferon gamma (IFNγ), Serum concentration of C-X-C Motif Chemokine Ligand 9 (CXCL9), (and 69 more...)
5y agoPRAHPRA Health Sciences collaborates with PWNHealth and Fulgent Genetics to provide at-home COVID-19 test capabilitiesGlobeNewswireRALEIGH, N.C., Dec. 17, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today the enhancement of its COVID-19 Monitoring Program with the addition of at-home COVID-19 testing...
5y agoPRAHPRA Health Sciences appoints senior FDA official to lead new Global Center of Excellence for Decentralized Clinical Trial StrategyGlobeNewswireRALEIGH, N.C. , Nov. 19, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today the appointment of Isaac Rodriguez-Chavez, PhD, MHS, MS, as Senior Vice President,...
6y agoPRAHPRA Health Sciences, Inc. Reports Third Quarter 2020 Results and Updates Full Year 2020 GuidanceGlobeNewswireNet new business of $737.9 million; representing growth of 10.2%; Net book-to-bill of 1.28 excluding reimbursement revenueNet new business of $986.0 million; Net book-to-bill of 1.35 including...
6y agoPRAHPRA Health Sciences to Report Third Quarter 2020 EarningsGlobeNewswireRALEIGH, N.C., Oct. 07, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its third quarter 2020 results after the market closes on Wednesday, November 4, 2020. The...
6y agoPRAHPRA Health Sciences selected by BARDA to be a member of its exclusive Clinical Studies NetworkGlobeNewswireWith the new contract, PRA will assist Biomedical Advanced Research and Development Authority (BARDA) in the development of medical countermeasures for public health RALEIGH, N.C., Oct. 06, 2020 ...
6y agoENTA PRAHA Study of EDP-297 in Healthy Subjects - NCT04559126ClinicalTrials.govSafety measured by adverse events, Cmax of EDP-297, AUC of EDP-297
6y agoPRAHPRA Health Sciences and Deep Lens announce strategic relationship to accelerate patient recruitment for precision cancer trialsGlobeNewswireRALEIGH, N.C. and COLUMBUS, Ohio, Sept. 18, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) and Deep Lens, Inc., announced today a new strategic relationship to accelerate patient...
6y agoPRAHPRA Health Sciences Announces Appointment of New DirectorGlobeNewswireRALEIGH, N.C., Sept. 15, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) today announced the appointment of Glen Stettin, M.D. to the Board of Directors of the Company, effective...
6y agoPRAHPRA Health Sciences Joins The Leukemia & Lymphoma Society on Global Trial for Children with Acute LeukemiaPR NewswireThe Leukemia & Lymphoma Society (LLS) and PRA Health Sciences (NASDAQ: PRAH) announced today a partnership to launch a first-of-its-kind global...
6y agoPRAHBioavailability and Food Effect Study of 3 Types of Carisbamate - NCT04520360ClinicalTrials.govIncidence of Treatment-Emergent Adverse Events
6y agoPRAHPRA Health Sciences, Inc. Reports Second Quarter 2020 Results and Provides Third Quarter and Full Year 2020 GuidanceGlobeNewswireNet new business of $701.6 million; Net book-to-bill of 1.35 excluding reimbursement revenueNet new business of $1,083.3 million; Net book-to-bill of 1.62 including reimbursement revenue$729.9 million...
6y agoPRAHPRA Health Sciences to Report Second Quarter 2020 EarningsGlobeNewswireRALEIGH, N.C., July 02, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its second quarter 2020 results after the market closes on Thursday, August 6, 2020. The...
6y agoPRAHPRA集成Microsoft Healthcare Bot服务以增强新冠肺炎监控计划GlobeNewswire北卡罗来纳州罗利市, June 12, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. （NASDAQ: PRAH ）今天宣布，将通过集成Microsoft Healthcare Bot服务提升其商业性Health Harmony新冠肺炎监控计划。PRA的Health...
6y agoPRAHPRA Enhances COVID-19 Monitoring Program with Integration of Microsoft Healthcare Bot ServiceGlobeNewswireRALEIGH, N.C., June 12, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today the enhancement of its commercial Health Harmony COVID-19 Monitoring Program with the...
6y agoPRAHPRA Health Sciences, Inc. Reports First Quarter 2020 Results, Withdraws Full Year 2020 Guidance Due to Uncertain COVID-19 Impact and Provides Second Quarter 2020 GuidanceGlobeNewswireNet new business of $604.7 million; Net book-to-bill of 1.10 excluding reimbursement revenueNet new business of $955.9 million; Net book-to-bill of 1.32 including reimbursement revenue$783.7 million...
6y agoPRAHPRA Health Sciences to Report First Quarter 2020 EarningsGlobeNewswireRALEIGH, N.C., April 13, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its first quarter 2020 results after the market closes on Thursday, April 30, 2020. The...
6y agoPRAHSymphony Health to provide free access to new MetysTM COVID-19 Module for U.S. based life sciences industry during pandemicGlobeNewswireRALEIGH, N.C., April 08, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today that Symphony Health, a PRA Health Sciences company, will make a 30-day license of its newly...
6y agoPRAHPRA Health Sciences expands remote clinical study support with its Mobile Health Platform during COVID-19 pandemicGlobeNewswireRALEIGH, N.C., March 24, 2020 (GLOBE NEWSWIRE) -- As a response to the ongoing global COVID-19 pandemic, PRA Health Sciences announced today the expansion of its industry-leading Mobile Health...
6y agoPRAHPRA Health Sciences Launches COVID-19 Monitoring ProgramGlobeNewswireRALEIGH, N.C., March 20, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences announced today the commercial availability of the COVID-19 Monitoring Program, a mobile app-driven, tiered initiative that...
6y agoPRAHSymphony Health Partners with Datavant for the Industry’s Deepest View of the Patient JourneyGlobeNewswireRALEIGH, N.C., March 11, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today a partnership between Symphony Health and Datavant that expands the breadth of data available for...
6y agoPRAHPRA Health Sciences, Inc. Reports Fourth Quarter and Full Year 2019 Results and Provides First Quarter and Full Year 2020 GuidanceGlobeNewswireNet new business of $658.9 million in the fourth quarter; Net book-to-bill of 1.21$800.2 million of revenue in the fourth quarter; 9.7% growth at actual foreign exchange rates and 10.2% growth on a...
6y agoPRAHPRA Health Sciences to Report Fourth Quarter 2019 EarningsGlobeNewswireRALEIGH, N.C., Feb. 03, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its fourth quarter and year end 2019 results after the market closes on Thursday, February 20,...
6y agoPRSP PRAHPerspecta and PRA Health Sciences complete successful modernization of Million Veteran Program for U.S. Department of Veterans AffairsPR NewswirePerspecta Inc. (NYSE: PRSP), a leading U.S. government services provider, in partnership with PRA Health Sciences (NASDAQ: PRAH), a leading contract...
7y agoPRAHPRA Health Sciences, Inc. Reports Third Quarter 2019 Results and Updates Full Year 2019 GuidanceGlobeNewswireNet new business of $669.4 million; Net book-to-bill of 1.22$780.7 million of total revenue; representing 8.8% growth at actual foreign exchange rates and 9.7% growth on a constant currency basisGAAP...
7y agoPRAHPRA Health Sciences to Report Third Quarter 2019 EarningsGlobeNewswireRALEIGH, N.C., Oct. 09, 2019 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its third quarter 2019 results after the market closes on Wednesday, October 30, 2019. The...
7y agoPRAHPRA Health Sciences, Symphony Health Launch Metys(TM) National Market Measurement ToolGlobeNewswireRALEIGH, N.C., Sept. 18, 2019 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today the launch of Symphony Health’s new national market measurement tool – Metys™ (pronounced...
7y agoPRAHPRA Health Sciences, Inc. Announces $500 Million Share Repurchase ProgramGlobeNewswireRALEIGH, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (the “Company”) (NASDAQ: PRAH) today announced that its Board of Directors (the “Board”) has authorized a $500 million...
7y agoPRAHPRA Health Sciences, Inc. Announces Secondary Offering and Concurrent Share RepurchaseGlobeNewswireRALEIGH, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (the “Company”) (NASDAQ: PRAH) today announced that KKR PRA Investors L.P. (the “Selling Stockholder”), intends to offer...